Allurion Technologies has treated its first commercial patients in the United States, marking its entry into the world's largest obesity market. The company is seeing demand from patients who discontinued GLP-1 therapy due to side effects, long-term commitment concerns or weight regain. The Allurion Program offers a non-surgical, non-pharmaceutical weight loss option. The procedure takes approximately 15 minutes and requires no endoscopy or anesthesia. Early feedback from trained centres has been encouraging, with clinicians highlighting the program's simplicity and scalability. Allurion is exploring partnerships with self-insured employers to expand patient access through employer-sponsored coverage. The company's platform combines the FDA-approved Allurion Gastric Balloon System with a virtual care suite including mobile apps and provider insights tools.

Allurion Technologies, a metabolically healthy weight loss company, has entered into an agreement for the immediate exercise of certain outstanding warrants to purchase up to 2,659,565 shares of common stock at a reduced exercise price of $1.15 per share. The company expects to raise approximately $3 million in gross proceeds before deducting financial advisory fees. The warrants were originally issued in January, February and November 2025. In exchange for the immediate exercise, warrant holders will receive new warrants to purchase up to 5,319,130 shares of common stock in a private placement. The new warrants will have an exercise price of $1.15 per share and a five-year term following stockholder approval. Roth Capital Partners is serving as financial adviser for the transaction, which is expected to close on 25 February 2026.